TY - JOUR
T1 - Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
AU - Quintás-Cardama, Alfonso
AU - Kantarjian, Hagop
AU - Ravandi, Farhad
AU - O'Brien, Susan
AU - Thomas, Deborah
AU - Vidal-Senmache, Gabriela
AU - Wierda, William
AU - Kornblau, Steven
AU - Cortes, Jorge
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/6/1
Y1 - 2009/6/1
N2 - BACKGROUND: The most frequent nonhematologic side effects associated with dasatinib therapy in patients with chronic myeloid leukemia (CML) are gastrointestinal, rash, and fluid retention syndromes. However, bleeding has been observed in some patients receiving dasatinib. In the current study, the authors investigated the risk factors and management of bleeding associated with dasatinib therapy for CML after imatinib failure. METHODS: The bleeding episodes associated with dasatinib therapy in 138 patients with CML who were consecutively treated at the study institution in clinical trials were evaluated. RESULTS: Bleeding occurred in 32 (23%) patients (grade ≥3 in 9 [7%] patients [according to National Cancer Institute Common Toxicity Criteria]), including in 12% of patients treated in chronic phase, 31% of patients treated in accelerated phase (AP), and 35% of patients treated in blast phase (BP) (P = .02). The majority of episodes (81%) affected the gastrointestinal tract. Basic coagulation studies were normal in 97% of patients who developed bleeding complications. Although 37% of episodes occurred with platelet counts >100 x 109/L, multivariate analysis identified thrombocytopenia and advanced phase CML as risk factors for bleeding. A trend toward an increased risk with a twice-daily schedule was observed (P = .17). Management included dasatinib interruption for a median of 17 days (range, 3-51 days) in 47%, of patients and transfusions in 72% of patients. CONCLUSIONS: Bleeding occurs during dasatinib therapy, particularly in patients with AP or BP disease and low platelet counts. Appropriate clinical monitoring and the timely interruption of dasatinib therapy are warranted in this subset of patients.
AB - BACKGROUND: The most frequent nonhematologic side effects associated with dasatinib therapy in patients with chronic myeloid leukemia (CML) are gastrointestinal, rash, and fluid retention syndromes. However, bleeding has been observed in some patients receiving dasatinib. In the current study, the authors investigated the risk factors and management of bleeding associated with dasatinib therapy for CML after imatinib failure. METHODS: The bleeding episodes associated with dasatinib therapy in 138 patients with CML who were consecutively treated at the study institution in clinical trials were evaluated. RESULTS: Bleeding occurred in 32 (23%) patients (grade ≥3 in 9 [7%] patients [according to National Cancer Institute Common Toxicity Criteria]), including in 12% of patients treated in chronic phase, 31% of patients treated in accelerated phase (AP), and 35% of patients treated in blast phase (BP) (P = .02). The majority of episodes (81%) affected the gastrointestinal tract. Basic coagulation studies were normal in 97% of patients who developed bleeding complications. Although 37% of episodes occurred with platelet counts >100 x 109/L, multivariate analysis identified thrombocytopenia and advanced phase CML as risk factors for bleeding. A trend toward an increased risk with a twice-daily schedule was observed (P = .17). Management included dasatinib interruption for a median of 17 days (range, 3-51 days) in 47%, of patients and transfusions in 72% of patients. CONCLUSIONS: Bleeding occurs during dasatinib therapy, particularly in patients with AP or BP disease and low platelet counts. Appropriate clinical monitoring and the timely interruption of dasatinib therapy are warranted in this subset of patients.
KW - Bleeding diathesis
KW - Chronic myelogenous leukemia
KW - Dasatinib
KW - Management
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=66649092089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66649092089&partnerID=8YFLogxK
U2 - 10.1002/cncr.24257
DO - 10.1002/cncr.24257
M3 - Article
C2 - 19280591
AN - SCOPUS:66649092089
SN - 0008-543X
VL - 115
SP - 2482
EP - 2490
JO - Cancer
JF - Cancer
IS - 11
ER -